Tyrosine kinase inhibitors raise major adverse cardiovascular event risk 2.13-fold in meta-analysis
Tyrosine kinase inhibitors linked to higher risk of heart problems
This meta-analysis of 9,068 patients found that tyrosine kinase inhibitors (TKIs) are associated with a significantly higher risk of major a…
Patients taking tyrosine kinase inhibitors face a significantly higher risk of serious heart issues, including high blood pressure and irreg…
EGFR inhibitors are associated with a 52.30% pooled incidence of all-grade rash in patients with tumors
EGFR inhibitors linked to rash in over half of patients
This meta-analysis of 65,116 patients receiving EGFR-targeted therapy found a pooled incidence of 52.30% for all-grade rash. Higher risks we…
A large analysis finds over half of patients on EGFR inhibitors develop a rash, with higher risk in Asian patients.